To evaluate the anti-lymphoma efficacy of the combination treatment in vivo, we choose a CDX model derived from ATM-deficient Granta-519 and treated the mice with inhibitors of PRMT5, and ATR, alone or together. Here, PRMT5 is linked to lymphoma.